Fairvalue-Calculator Fairvalue-Calculator
EN DE

SynAct Pharma AB (SYNACT) Fair Value & Analysis

Healthcare · SE · Market cap 755M SEK

Pricekr 15.20
Fair Valuekr 13.68
Upside-10.0%
Quality95/100
Evidence: Low Range kr 10.26 – kr 17.11

Fair value as of: Jun 24, 2026

Analysis

SynAct Pharma AB (SYNACT) currently trades at kr 15.20, while our model-based Fair Value estimate is kr 13.68 — implying the stock looks roughly 10.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is SynAct Pharma AB (SYNACT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 13.68 versus a price of kr 15.20 — about −10% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SYNACT?
Our 21-model fair value for SynAct Pharma AB is kr 13.68 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 15.20.
What is the quality score of SYNACT?
SynAct Pharma AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.